Baricitinib Powder ...

Baricitinib Powder Material Anti-Rheumatism

Baricitinib Powder Material Anti-Rheumatism

Min.Order / FOB Price:Get Latest Price

1 Kilogram

Negotiable

  • Min.Order :1 Kilogram
  • Purity: 99
  • Payment Terms : L/C,T/T,

Keywords

Artemisinin Artemisinin powder 99% Artemisinin

Quick Details

  • Appearance:white
  • Application:Artemisia annua is used as antimalarial drugs.
  • PackAge:drum
  • ProductionCapacity:1000|Kilogram|Day
  • Storage:room
  • Transportation:

Superiority:

Baricitinib Powder Material  Anti-Rheumatism  

Product Name    Baricitinib 
Appearance    White Powder
CAS No.    1187594-09-7 
MF    C16H17N7O2S 

Baricitinib, sold under the brand name Olumiant among others, is a drug for the treatment of rheumatoid arthritis (RA) in adults whose disease was not well controlled using RA medications called tumor necrosis factor (TNF) antagonists. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.  

Baricitinib (baricitinib) obtained FDA emergency authorization (EUA) to be used in combination with Redecivir to treat patients who require supplemental oxygen, intubation ventilation or extracorporeal membrane oxygenation, children over 2 years of age, or adult hospitalized patients with new coronary pneumonia or Suspected patient. The FDA emergency authorization is based on a clinical trial (ACTT-2) conducted by the National Institute of Allergy and Infectious Diseases (ACTT-2). Compared with radcivir monotherapy, baritinib is combined with radcivir.  

Details:

Baricitinib Powder Material  Anti-Rheumatism  

Product Name    Baricitinib 
Appearance    White Powder
CAS No.    1187594-09-7 
MF    C16H17N7O2S 

Baricitinib, sold under the brand name Olumiant among others, is a drug for the treatment of rheumatoid arthritis (RA) in adults whose disease was not well controlled using RA medications called tumor necrosis factor (TNF) antagonists. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.  

Baricitinib (baricitinib) obtained FDA emergency authorization (EUA) to be used in combination with Redecivir to treat patients who require supplemental oxygen, intubation ventilation or extracorporeal membrane oxygenation, children over 2 years of age, or adult hospitalized patients with new coronary pneumonia or Suspected patient. The FDA emergency authorization is based on a clinical trial (ACTT-2) conducted by the National Institute of Allergy and Infectious Diseases (ACTT-2). Compared with radcivir monotherapy, baritinib is combined with radcivir.  

View All
Visit Store

You Might Also Like

Related Searches

Contact Supplier

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View